PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-EU expects to get more than a billion COVID-19 shots by September

Tue, 25th May 2021 10:23

* EU to easily meet vaccination targets, 1.5 bln doses by
year-end

* Doses coming from four drugmakers, not Sanofi, CureVac
-document

* EU leaders back goal of donating at least 100 mln doses in
2021

* WHO's Tedros asks for much more
(Adds von der Leyen quotes)

By Sabine Siebold and Francesco Guarascio

BRUSSELS, May 25 (Reuters) - The European Union expects to
have received more than a billion doses of COVID-19 vaccines by
the end of September from four drugmakers, according to a
document presented to EU leaders on Tuesday.

The document, seen by Reuters and prepared by the European
Commission, shows the EU is confident of having enough vaccines
to immunise its entire eligible population by that date, well
beyond the initial goal of inoculating 70% of the adult
population by the end of the summer.

"We are on track to reach our goal," the head of the
European Commission, Ursula von der Leyen, told a news
conference after the meeting with EU leaders. "If we continue
like this, we have confidence that we will be able to safely
reopen our societies."

The EU expects to get 413 million doses in the second
quarter, and another 529 million in the third, according to the
EU document. It received 106 million in the first quarter.

By the end of the year, the EU forecasts it will receive
another 452 million doses, for a total of 1.5 billion.

The estimates take into account only vaccines from
Pfizer/BionTech , Johnson & Johnson,
AstraZeneca and Moderna.

They exclude doses from German biotech CureVac and
French drugmaker Sanofi, which have signed contracts
with the EU for hundreds of millions of doses but are struggling
to develop their vaccines and get them approved by EU
regulators.

The numbers are in line with public commitments and previous
announcements, but also include previously unknown targets for
the second half of the year.

The EU has also said it plans to share at least 100 million
doses this year with poorer nations outside the bloc
.

EU leaders meeting on Tuesday confirmed that commitment in a
joint document, but did not make it more ambitious. Some
vaccines could also be used for a third booster shot or against
variants.

World Health Organization (WHO) director-general Tedros
Adhanom Ghebreyesus thanked the EU for its commitment, but
added: "We need hundreds of millions more doses."

He has also urged rich nations to reconsider plans to
vaccinate teenagers because those vaccines would be more useful
in poorer nations.

Despite Tedros' call, von der Leyen said on Tuesday she
hoped the Pfizer/BioNTech vaccine could be quickly approved by
the EU drugs regulator for teenagers between 12 and 15, noting
that a decision was expected towards the end of the month.

The COVAX programme for distributing vaccines around the
world, backed by the WHO and the Global Alliance for Vaccines
and Immunization (GAVI), has so far shipped only about 70
million vaccine doses of the 2 billion planned for this year, as
wealthy nations have reserved most of those available.

LION'S SHARE

Pfizer and BioNTech's vaccine accounts for more than half
the supplies in the second quarter of this year and for nearly
40% of total deliveries in the third quarter.

The document shows that the two companies will deliver 200
million doses in the July-September period, nearly completing
their contracted commitment to supply 600 million.

The two drugmakers are expected to deliver roughly 200
million doses more in the fourth quarter, the bulk of which
would come from a third contract for up to 1.8 billion doses
signed in May, which runs until 2023.

A Pfizer spokesman declined to comment on the numbers cited
in the EU document.

Deliveries in the second half of the year also include
several million from AstraZeneca, even though it had been
required to deliver all its 300 million contracted doses by the
end of June.

The company said in March it could hope to deliver only 100
million doses to the EU by the end of June due to production
problems and export restrictions.

The EU document is based on the company's estimates rather
than on the EU request to deliver 120 million doses by the end
of the second quarter.

That request was made by EU lawyers in a Brussels court this
month. A ruling is expected next month.
(Reporting by Sabine Siebold and Francesco Guarascio
@fraguarascio in Brussels; additional reporting by Stephanie
Ulmer-Nebehay in Geneva; Editing by John Chalmers, Barbara Lewis
and Nick Macfie)

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.